FGEN FibroGen, Inc.Stock Price & Overview
$1.16
Charts
Quant Ranking
FGEN Analysis
FGEN News
Latest Headlines
Ratings Summary
People Also Follow
Similar to FGEN
ETFs Holding FGEN
FGEN Company Profile
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
FGEN Revenue
FGEN Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
Dividends
FGEN Ownership
FGEN Peers
Risk
Technicals
FGEN Transcripts
Investor Presentations
FGEN SEC Filings
Press Releases
FGEN Income Statement
FGEN Balance Sheet
FGEN Cash Flow Statement
FGEN Long Term Solvency
Discover More
You may be interested in: